-
Hoechst 33342/PI Double Staining Kit Workflow
2026-08-23
Learn how to use Hoechst 33342/PI Double Staining Kit K2237 to separate normal, apoptotic, and necrotic cell phenotypes by combining nuclear morphology with membrane integrity. The workflow translates findings from renal cell carcinoma research into practical controls, imaging choices, and troubleshooting strategies for natural-product studies.
-
Firefly Luciferase mRNA: A Decision Framework
2026-08-22
Firefly Luciferase mRNA (ARCA, 5-moUTP) is more than a luminescent tag: it is a controllable probe for separating delivery, translation, and biological response. This guide connects transcript design with assay normalization, formulation choices, and in vivo interpretation.
-
Quercetin: From PI3K Inhibition to Translation
2026-08-21
Quercetin is best understood as a pleiotropic research probe that connects PI3K signaling, mitochondrial apoptosis, cell cycle regulation, and inflammation. New evidence from an LPS-induced depression model expands its translational relevance beyond cancer research while highlighting the need for disciplined validation, formulation control, and mechanistic attribution.
-
Tunicamycin: From ER Stress to Glyco-Oncology
2026-08-20
Tunicamycin offers translational researchers a mechanistically defined way to connect N-glycosylation, ER stress, inflammation, and tumor immunobiology. Its value is greatest when pharmacological stress induction is integrated with STT3A–FCN3 genetics, glycoprotein validation, and carefully bounded interpretation.
-
U0126: Selective MEK1/2 Inhibitor for MAPK Research
2026-08-20
U0126 is a cell-permeable, non-ATP-competitive MEK1/2 inhibitor that suppresses ERK1/2 phosphorylation and supports MAPK/ERK signaling pathway inhibition. In a cellular C9ORF72 poly-Gly-Ala model, U0126 reduced tau phosphorylation, tau aggregation, and cell death, linking MEK–ERK pharmacology to neurobiology research.
-
Ether Lipids Shape B-Cell Humoral Immunity
2026-08-19
This study provides causal evidence that B-cell-intrinsic ether lipid biosynthesis, mediated by the peroxisomal enzyme PexRAP, supports germinal-center development, antibody production, and affinity maturation. By combining inducible Dhrs7b loss-of-function models with imaging mass spectrometry and immunization experiments, the authors connect lipid composition to B-cell survival through control of reactive oxygen species and membrane peroxidation.
-
Leucovorin Calcium in Methotrexate Rescue Models
2026-08-19
Leucovorin Calcium, also called calcium folinate, supplies a reduced folate rationale for studying methotrexate rescue and the folate metabolism pathway. Its defined aqueous solubility and frozen-storage specification support controlled cell proliferation assays, while gastric cancer assembloid evidence shows why stromal context should be included when evaluating drug response.
-
Wnt Agonist 1: A Causal Test for Wnt–GPX4
2026-08-18
Wnt agonist 1 (BML-284) provides a controlled way to test how canonical Wnt signaling influences transcription, differentiation, and redox phenotypes. This article develops an assay strategy that connects TCF activity with the Wnt/NR2F2/GPX4 chemoresistance axis while distinguishing established evidence from testable research hypotheses.
-
CCG-1423 RhoA Inhibitor Workflow Guide
2026-08-18
CCG-1423 is a pathway-level RhoA inhibitor for separating MRTF-A nuclear signaling from actin-dependent cytoskeletal effects. This guide shows how to apply it in cancer research, build mechanistic controls, and cautiously extend the workflow to RhoA/ROCK-dependent barrier and viral-entry models.
-
AG-490 for JAK2/STAT6 Macrophage Studies
2026-08-17
Use AG-490 as a pharmacological probe to test whether hepatoma-derived exosomes drive macrophage polarization through JAK2-linked signaling. This workflow combines dose-aware pathway inhibition, exosome quality controls, phosphoprotein analysis, and functional validation for more defensible cancer research results.
-
AZD3463 Workflow for ALK/IGF1R Inhibition
2026-08-17
AZD3463 combines ALK and IGF1R pathway coverage with practical workflows for neuroblastoma signaling, apoptosis, autophagy, and combination studies. This guide connects dose-response design, mutant ALK models, pathway validation, and troubleshooting to reproducible bench execution.
-
JSH-23: Reliable NF-κB Assay Design
2026-08-16
JSH-23 (SKU B1645) is a small-molecule NF-κB inhibitor for dissecting p65 nuclear localization, inflammatory transcription, and cytokine responses in cell and animal models. This scenario-based guide explains solvent handling, dose selection, controls, interpretation, and vendor evaluation for more defensible inflammation research.
-
Clarithromycin CYP3A Assay Workflow
2026-08-15
Build more interpretable CYP3A inhibition experiments with Clarithromycin, from solvent handling and concentration-response design to pathway-specific controls. The workflow links statin metabolism interaction and anticoagulant pharmacology questions without confusing CYP3A effects with non-CYP clearance pathways.
-
Tamoxifen: SERM Mechanisms and Research Use
2026-08-14
Tamoxifen is a selective estrogen receptor modulator used in breast cancer research and CreER-mediated gene knockout workflows. Evidence supports tissue-selective estrogen receptor activity, while mouse data show that high-dose prenatal exposure can cause developmental malformations.
-
SB 431542 Workflow for ALK5 Signaling Studies
2026-08-14
Use SB 431542 as a pathway-dissection tool to connect ALK5 activity with Smad2 phosphorylation, EMT, proliferation, and invasion. This practical workflow also shows how to distinguish mechanism-focused experiments from broader glioma and anti-tumor immunology applications.